No Data
No Data
Lucy Therapeutics Appoints Kim Drapkin as Board Chair
Achieve, INmune, Lenz Gain on Bullish Initiations From Raymond James
Raymond James Initiates LENZ Therapeutics(LENZ.US) With Buy Rating, Announces Target Price $37
LENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ Therapeutics, Inc. (LENZ) Q2 2024 Earnings Call Transcript
LENZ Therapeutics Price Target Maintained With a $36.00/Share by Piper Sandler
No Data
No Data